Drugmaker Abbott India reported a rise in second-quarter profit on Thursday, helped by strong demand for its gastrointestinal and anti-infective medications.

Abbott India continued to benefit from anti-infectives and medications for gastrointestinal conditions, the company said ...

Sadly, Nigeria is among the countries atop the list of counterfeit drug ... For instance, since the exit of GSK, a leading manufacturer of inhalers for asthma patients, the price of inhalers ...

GSK acquired an experimental therapy from Chimagen Biosciences, paying $300 million upfront for the “T-cell engager” therapy, ...

The main patent on Advair (fluticasone+salmeterol) expired as long ago as 2010, while the patent on GSK’s Diskus inhaler expired ... a significantly discounted list price, we will demonstrate ...

The FTC warned in September that it may consider legal action against companies who list new patents ... Boehringer Ingelheim, and GSK also announced commitments to cap inhaler out-of-pocket ...

The Department of Pharmaceuticals (DoP) has upheld a price ceiling order issued by the National Pharmaceutical Pricing ...

China’s probe into AstraZeneca Plc has reached its uppermost echelons, ensnaring local president Leon Wang and throwing into question the future of the most successful Western pharmaceutical company ...

Animal testing remains widespread, but the long history of campaigning against it has made some inroads, with some sectors pioneering alternative methods and scientists highlighting its shortcomings.A ...

In a strategic move to enhance their immunology portfolio, GSK has announced an agreement to acquire experimental ... Foundation of America for updates on CMG1A46. Learn more about medications used to ...

However, early versions of fatty spheres for mRNA delivery won’t work for inhalable medications because the nanoparticles ...

GlaxoSmithKline Pharmaceuticals Limited is ... cephalexin was commenced at Ankleshwar and the salbutamol inhalers at Nashik. Glaxo rated amongst the first five of Indias most respected companies ...